Igor P Dmitriev
Overview
Explore the profile of Igor P Dmitriev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hassan A, Shrihari S, Gorman M, Ying B, Yuan D, Raju S, et al.
Cell Rep
. 2021 Jul;
36(4):109452.
PMID: 34289385
SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine efficacy. We recently reported the protective activity of an intranasally administered spike protein-based chimpanzee adenovirus-vectored vaccine (ChAd-SARS-CoV-2-S) in animals, which has...
12.
Lee M, Lu Z, Shoemaker C, Tremblay J, St Croix B, Seaman S, et al.
J Control Release
. 2021 Apr;
334:106-113.
PMID: 33872627
For the developing field of gene therapy the successful address of the basic requirement effective gene delivery has remained a critical barrier. In this regard, the "Holy Grail" vector envisioned...
13.
Agarwal P, Gammon E, Sandey M, Lindley S, Koehler J, Matz B, et al.
Heliyon
. 2021 Feb;
7(2):e06210.
PMID: 33615011
Osteosarcoma is one among the most common neoplasms in dogs. Current treatments show limited efficacy and fail to prevent metastasis. Conditionally replicative adenoviruses (CRAd) replicate exclusively in targeted tumor cells...
14.
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
Hassan A, Kafai N, Dmitriev I, Fox J, Smith B, Harvey I, et al.
Cell
. 2020 Sep;
183(1):169-184.e13.
PMID: 32931734
The coronavirus disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a prefusion stabilized...
15.
Lu Z, Dmitriev I, Brough D, Kashentseva E, Li J, Curiel D
J Virol
. 2020 Feb;
94(10).
PMID: 32102889
Human adenoviruses have many attractive features for gene therapy applications. However, the high prevalence of preexisting immunity against these viruses in general populations worldwide has greatly limited their clinical utility....
16.
Lee M, Lu Z, Li J, Kashentseva E, Dmitriev I, Mendonca S, et al.
Mol Cancer Ther
. 2020 Jan;
19(3):966-971.
PMID: 31907220
The application of cancer gene therapy has heretofore been restricted to local, or locoregional, neoplastic disease contexts. This is owing to the lack of gene transfer vectors, which embody the...
17.
Hassan A, Dmitriev I, Kashentseva E, Zhao H, Brough D, Fremont D, et al.
Cell Rep
. 2019 Sep;
28(10):2634-2646.e4.
PMID: 31484074
The teratogenic potential of Zika virus (ZIKV) has made the development of an effective vaccine a global health priority. Here, we generate two gorilla adenovirus-based ZIKV vaccines that encode for...
18.
Gonzalez-Pastor R, Ashshi A, El-Shemi A, Dmitriev I, Kashentseva E, Lu Z, et al.
J Ovarian Res
. 2019 Feb;
12(1):18.
PMID: 30767772
Background: Virotherapy represents a promising approach for ovarian cancer. In this regard, conditionally replicative adenovirus (CRAd) has been translated to the context of human clinical trials. Advanced design of CRAds...
19.
Fonseca J, McCaffery J, Caceres J, Kashentseva E, Singh B, Dmitriev I, et al.
Vaccine
. 2018 Apr;
36(20):2799-2808.
PMID: 29657070
Introduction: Cellular and humoral immune responses are both involved in protection against Plasmodium infections. The only malaria vaccine available, RTS,S, primarily induces short-lived antibodies and targets only a pre-erythrocytic stage...
20.
Kuroki L, Jin X, Dmitriev I, Kashentseva E, Powell M, Mutch D, et al.
PLoS One
. 2017 Dec;
12(12):e0190125.
PMID: 29267342
Clinical application of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based cancer therapeutics has not reached optimal potencies in part due to inadequate drug stability and inefficiencies in cancer-selective drug delivery. As...